Jill M. Quigley Sells 8,760 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley sold 8,760 shares of the firm’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $5.79, for a total value of $50,720.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Terns Pharmaceuticals Trading Down 1.4 %

Terns Pharmaceuticals stock opened at $5.63 on Wednesday. The firm’s 50 day simple moving average is $6.32 and its 200 day simple moving average is $7.40. Terns Pharmaceuticals, Inc. has a 1-year low of $4.32 and a 1-year high of $11.40. The firm has a market capitalization of $478.21 million, a PE ratio of -4.77 and a beta of -0.31.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. Research analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Institutional Trading of Terns Pharmaceuticals

Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in Terns Pharmaceuticals by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 154,714 shares of the company’s stock valued at $1,290,000 after purchasing an additional 1,994 shares in the last quarter. Bleakley Financial Group LLC increased its holdings in shares of Terns Pharmaceuticals by 26.0% in the 3rd quarter. Bleakley Financial Group LLC now owns 13,312 shares of the company’s stock worth $111,000 after buying an additional 2,751 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Terns Pharmaceuticals by 28.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,645 shares of the company’s stock worth $154,000 after buying an additional 5,049 shares during the last quarter. Creative Planning raised its position in shares of Terns Pharmaceuticals by 27.2% during the 3rd quarter. Creative Planning now owns 25,310 shares of the company’s stock valued at $211,000 after buying an additional 5,409 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Terns Pharmaceuticals during the 3rd quarter worth $48,000. Institutional investors own 98.26% of the company’s stock.

Wall Street Analysts Forecast Growth

TERN has been the subject of several recent research reports. HC Wainwright reissued a “neutral” rating and issued a $7.50 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. JMP Securities reaffirmed a “market outperform” rating and issued a $20.00 price objective on shares of Terns Pharmaceuticals in a report on Wednesday, December 4th. Oppenheimer increased their target price on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $26.00 price target (up from $19.00) on shares of Terns Pharmaceuticals in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Terns Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $18.30.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.